Myco Industries, Inc. Announces U.S. Patent and Trademark Office Has Issued U.S. Patent No. 10,404203 for the AB Max™

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Today Myco Industries, Inc. (Myco), a privately held medical device company, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,404203 on September 3, 2019 for the AB Max™ – a new advanced doctor’s treatment for Anterior Blepharitis*.

John Choate, Chairman of Myco designed the AB Max™ to provide medical professionals with advanced functionality utilizing two onboard computers and proprietary tips specifically designed to treat Anterior Blepharitis*. As the U.S. Patent Office recognized, AB Max™ is a unique advancement over our competitor’s device since Myco’s patent covers the revolutionary pulse-mode feature of the AB Max™ after reviewing our competitors’ patent.

The AB Max™ offers the same forward and reverse functionality as our competitor, but also has a patented PULSE mode specifically engineered to remove even the most tenacious scurf and debris, while massaging the outer eyelid margins for better patient outcomes.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles